ProMIS Neurosciences R&D Soars, Net Loss Widens to $29M

TL;DR

**ProMIS is burning cash fast on R&D, betting big on its pipeline; it's a high-risk, high-reward play for traders.**

AI Summary

ProMIS Neurosciences Inc. reported a significant net loss of $29,045,059 for the nine months ended September 30, 2025, a stark contrast to the net income of $3,017,080 for the same period in 2024. This shift was primarily driven by a substantial increase in research and development expenses, which surged to $24,011,452 in 2025 from $6,313,373 in 2024, reflecting intensified efforts in its neurodegenerative disease pipeline. The company's cash position increased to $15,399,165 as of September 30, 2025, up from $13,291,167 at December 31, 2024, largely due to successful financing activities. ProMIS raised $20,944,671 from financing activities in the nine months ended September 30, 2025, including proceeds from ATM offerings, registered direct offerings, and discounted warrant exercises. Total operating expenses more than doubled to $29,395,189 from $10,825,033 year-over-year. The company is focused on developing antibody therapies for Alzheimer's disease (PMN310), ALS (PMN267), and multiple system atrophy (PMN442), with PMN310 being its lead product candidate. The accumulated deficit widened to $119,732,132 by September 30, 2025, from $90,687,073 at December 31, 2024, indicating continued investment in its drug discovery platform.

Why It Matters

This filing reveals ProMIS Neurosciences is aggressively investing in its R&D pipeline, particularly for PMN310, PMN267, and PMN442, which could be a make-or-break strategy for investors. The substantial increase in net loss to $29 million, while concerning on the surface, is a direct result of this increased R&D spend, signaling a critical phase in drug development. For employees, this indicates job security and potential growth as the company pushes its candidates through preclinical and clinical stages. Customers and the broader market could benefit significantly if these therapies for Alzheimer's, ALS, and MSA prove successful, potentially disrupting the competitive landscape in neurodegenerative disease treatment.

Risk Assessment

Risk Level: high — The company reported a net loss of $29,045,059 for the nine months ended September 30, 2025, and an accumulated deficit of $119,732,132. This significant cash burn, coupled with the early-stage nature of its product candidates (PMN310, PMN267, PMN442 are in preclinical stages), indicates substantial operational and financial risk, as success is highly dependent on future clinical trial outcomes and regulatory approvals.

Analyst Insight

Investors should monitor ProMIS Neurosciences' progress on its lead product candidates, PMN310, PMN267, and PMN442, for any preclinical or clinical trial updates. Given the high R&D spend and net loss, consider this a speculative investment with potential for significant upside if drug development is successful, but also substantial downside if trials fail.

Financial Highlights

debt To Equity

1.34

revenue

$0

operating Margin

N/A

total Assets

$21,458,147

total Debt

$12,270,792

net Income

$-29,045,059

eps

$-0.78

gross Margin

N/A

cash Position

$15,399,165

revenue Growth

N/A

Key Numbers

• $29,045,059 — Net Loss (For the nine months ended September 30, 2025, compared to $3,017,080 net income in 2024.)
• $24,011,452 — Research and Development Expenses (For the nine months ended September 30, 2025, up from $6,313,373 in 2024.)
• $15,399,165 — Cash (As of September 30, 2025, an increase from $13,291,167 at December 31, 2024.)
• $20,944,671 — Net Cash Provided by Financing Activities (For the nine months ended September 30, 2025, funding operations and R&D.)
• $119,732,132 — Accumulated Deficit (As of September 30, 2025, indicating significant historical losses.)
• 53,811,110 — Common Shares Outstanding (As of November 12, 2025, reflecting recent equity issuances.)
• $0.78 — Net Loss Per Share, Basic (For the nine months ended September 30, 2025, compared to $0.13 net income per share in 2024.)
• $12,211,047 — Total Current Liabilities (As of September 30, 2025, up from $2,218,425 at December 31, 2024, driven by accounts payable and accrued liabilities.)

Key Players & Entities

• ProMIS Neurosciences Inc. (company) — Registrant and developer of antibody therapies
• SEC (regulator) — Securities and Exchange Commission
• Nasdaq Capital Market (market) — Exchange where Common Shares are registered
• PMN310 (product) — Lead product candidate for Alzheimer's disease
• PMN267 (product) — Second lead product candidate targeting ALS
• PMN442 (product) — Third lead product candidate targeting MSA and Parkinson's disease
• Alzheimer's disease (disease) — Focus of PMN310
• multiple system atrophy (disease) — Focus of PMN442
• amyotrophic lateral sclerosis (disease) — Focus of PMN267
• Bloomberg (publication) — Financial news outlet

FAQ

Risk Factors

• Significant Net Loss and Accumulated Deficit [high — financial]: The company reported a net loss of $29,045,059 for the nine months ended September 30, 2025, a substantial increase from the prior year's net income of $3,017,080. The accumulated deficit has widened to $119,732,132 as of September 30, 2025, indicating a history of significant losses and ongoing investment in its pipeline.
• High Research and Development Expenses [high — operational]: Research and development expenses surged to $24,011,452 for the nine months ended September 30, 2025, from $6,313,373 in the same period of 2024. This significant increase reflects intensified efforts in its neurodegenerative disease pipeline, which is crucial for future revenue but also a major drain on current resources.
• Dependence on Financing Activities [high — financial]: ProMIS raised $20,944,671 from financing activities in the nine months ended September 30, 2025, to fund operations and R&D. The company's cash position of $15,399,165 as of September 30, 2025, while increased, is dependent on continued successful financing, which can be volatile.
• Increased Current Liabilities [medium — financial]: Total current liabilities more than quintupled to $12,211,047 as of September 30, 2025, from $2,218,425 at December 31, 2024. This increase is primarily driven by a significant rise in accounts payable and accrued liabilities, potentially indicating short-term cash flow pressures.
• Intense Competition in Neurodegenerative Diseases [high — market]: The company is developing therapies for Alzheimer's, ALS, and multiple system atrophy, highly competitive and complex therapeutic areas. Success is not guaranteed, and the market is crowded with established pharmaceutical companies and numerous biotech firms also pursuing treatments.
• Lengthy and Uncertain Drug Development Process [high — regulatory]: Developing new drugs is a lengthy, expensive, and highly regulated process. ProMIS faces significant regulatory hurdles, clinical trial risks, and the possibility of failure at any stage, which could render its investments worthless.

Industry Context

ProMIS Neurosciences operates in the highly competitive and capital-intensive biotechnology sector, specifically targeting neurodegenerative diseases like Alzheimer's, ALS, and multiple system atrophy. This field is characterized by long development cycles, high failure rates, and significant investment requirements, with numerous established pharmaceutical companies and emerging biotechs vying for breakthroughs.

Regulatory Implications

The development of novel therapies for neurodegenerative diseases is subject to stringent regulatory oversight by bodies such as the FDA. ProMIS must navigate complex clinical trial protocols, manufacturing standards, and approval processes, with any delays or failures posing significant risks to its pipeline and financial viability.

What Investors Should Do

1. Monitor R&D spending and clinical trial progress closely.
2. Evaluate the company's ability to secure future financing.
3. Assess the competitive landscape for Alzheimer's and ALS treatments.
4. Review the increasing current liabilities and cash burn rate.

Key Dates

• 2025-09-30: Nine months ended September 30, 2025 financial results reported — Revealed a significant net loss of $29,045,059 and a substantial increase in R&D expenses, highlighting increased investment in pipeline development.
• 2025-09-30: Condensed Consolidated Balance Sheets as of September 30, 2025 — Showed an increased cash position of $15,399,165 and a widening accumulated deficit of $119,732,132.
• 2024-12-31: Condensed Consolidated Balance Sheets as of December 31, 2024 — Provided the comparative baseline for the 2025 period, showing a cash position of $13,291,167 and an accumulated deficit of $90,687,073.

Glossary

Accumulated deficit

The total cumulative net losses of a company since its inception, minus any cumulative net income. (Indicates the company's historical profitability and the extent of its cumulative losses, which stood at $119,732,132 as of September 30, 2025.)

ATM offerings

At-the-market offerings, where a company sells shares of its stock on a public stock exchange over a period of time. (A method used by ProMIS to raise capital, contributing to the $20,944,671 raised from financing activities in the nine months ended September 30, 2025.)

PIPE

Private Investment in Public Equity, a type of financing where an institutional investor buys stock directly from a publicly traded company at a discount. (Mentioned in the context of a loss on issuance in July 2024, indicating past financing activities and their associated costs.)

Warrant exercises

The act of a warrant holder buying the underlying stock at a specified price, often at a discount. (A source of capital for ProMIS, contributing to the $20,944,671 raised from financing activities in the nine months ended September 30, 2025.)

Weighted-average outstanding Common Shares, basic

The average number of common shares outstanding during a period, used for calculating basic earnings per share. (Essential for understanding the per-share impact of the company's net loss, which was $0.78 per share for the nine months ended September 30, 2025.)

Year-Over-Year Comparison

Compared to the prior year's nine-month period, ProMIS Neurosciences has shifted from a net income of $3,017,080 to a net loss of $29,045,059, primarily due to a more than threefold increase in R&D expenses to $24,011,452. Total operating expenses more than doubled year-over-year. While cash reserves have increased to $15,399,165 due to successful financing activities totaling $20,944,671, the accumulated deficit has grown substantially to $119,732,132, indicating a significant increase in investment and operational costs.

Filing Documents

• pmn-20250930x10q.htm (10-Q) — 1833KB
• pmn-20250930xex10d2.htm (EX-10.2) — 48KB
• pmn-20250930xex31d1.htm (EX-31.1) — 9KB
• pmn-20250930xex31d2.htm (EX-31.2) — 9KB
• pmn-20250930xex32d1.htm (EX-32.1) — 10KB
• 0001104659-25-109719.txt ( ) — 7563KB
• pmn-20250930.xsd (EX-101.SCH) — 56KB
• pmn-20250930_cal.xml (EX-101.CAL) — 33KB
• pmn-20250930_def.xml (EX-101.DEF) — 196KB
• pmn-20250930_lab.xml (EX-101.LAB) — 424KB
• pmn-20250930_pre.xml (EX-101.PRE) — 328KB
• pmn-20250930x10q_htm.xml (XML) — 1402KB

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 23 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 32 Item 4.

Controls and Procedures

Controls and Procedures 33 PART II OTHER INFORMATION 33 Item 1.

Legal Proceedings

Legal Proceedings 33 Item 1A.

Risk Factors

Risk Factors 34 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 35 Item 3. Defaults Upon Senior Securities 35 Item 4. Mine Safety Disclosures 35 Item 5. Other Information 35 Item 6. Exhibits 36

Signatures

Signatures 37 Table of Contents DISCLOSURE REGARDING FORWARD-LOOKING STATEMENTS This Quarterly Report on Form 10-Q contains statements that we believe are, or may be considered to be, "forward-looking statements." Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based on current beliefs, expectations or assumptions regarding the future of the business, future plans and strategies, operational results and other future conditions of the Company. All statements other than statements of historical fact included in this Quarterly Report on Form 10-Q regarding the prospects of our industry or our prospects, plans, financial position or business strategy may constitute forward-looking statements. In addition, forward-looking statements generally can be identified by the use of forward-looking words such as "plans," "expects" or "does not expect," "is expected," "look forward to," "budget," "scheduled," "estimates," "forecasts," "will continue," "intends," "the intent of," "have the potential," "anticipates," "does not anticipate," "believes," "should," "should not," or variations of such words and phrases that indicate that certain actions, events or results "may," "could," "would," "might," or "will," "be taken," "occur," or "be achieved," or the negative of these terms or variations of them or similar terms. Furthermore, forward-looking statements may be included in various filings that we make with the Securities and Exchange Commission (" SEC ") or press releases or oral statements made by or with the approval of one of our authorized executive officers. Although we believe that the expectations reflected in these forward-looking statements are reasonable, we cannot assure you that these expectations will prove to be correct. These forward-looking statements are subject to certain known and unknown risks and uncertainties, as well as assumptions that could cause actual results to differ materially fr

Forward-looking statements contained in this Quarterly Report on Form 10-Q include, but are not limited to

Forward-looking statements contained in this Quarterly Report on Form 10-Q include, but are not limited to: the anticipated amount, timing and accounting of contingent, milestone, royalty and other payments under licensing or collaboration agreements; tax positions and contingencies; research and development costs; compensation and other selling, general and administrative expense; foreign currency exchange risk; estimated fair value of assets and liabilities; and impairment assessments; the potential impact of increased competition in the markets in which we compete; patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; our plans and investments in our portfolio as well as implementation of our corporate strategy; the risk that we will maintain enough liquidity to execute our business plan and our ability to continue as a going concern; our expected use of proceeds from sales of our common shares or common share equivalents in offerings or "at-the-market" offerings and the period over which such proceeds, together with existing cash, will be sufficient to meet our operating needs; our efforts to maintain our listing on Nasdaq; the drivers for growing our business, including our plans and intention to commit resources relating to discovery, research and development programs and business development opportunities as well as the potential benefits and results of, and the anticipated completion of, certain business development transactions; the expectations, development plans and anticipated timelines, including costs and timing of clinical trials, filings and approvals, of our products candidates and pipeline programs, including collaborations with third-parties, as well as the potential therapeutic scope of the development and commercialization of our and our collaborators' pipeline product candidates, if approved; the timing, outcome and impact of administrative, regulatory, legal and

—FINANCIAL INFORMATION

PART I—FINANCIAL INFORMATION

Financial Statements

Item 1. Financial Statements. PROMIS NEUROSCIENCES INC. Condensed Consolidated Balance Sheets (expressed in US dollars, except share amounts) (Unaudited) September 30, December 31, 2025 2024 Assets Current assets: Cash $ 15,399,165 $ 13,291,167 Short-term investments 33,051 33,051 Prepaid expenses and other current assets 6,025,931 5,587,238 Total current assets 21,458,147 18,911,456 Total assets $ 21,458,147 $ 18,911,456 Liabilities and Shareholders' Equity Current liabilities: Accounts payable $ 4,211,485 $ 1,737,463 Accrued liabilities 7,999,562 480,962 Total current liabilities 12,211,047 2,218,425 Share-based compensation liability 54,153 199,263 Warrant liability 5,592 5,592 Total liabilities 12,270,792 2,423,280 Commitments and contingencies Shareholders' equity: Common Shares, no par value, unlimited shares authorized, 53,811,110 and 32,689,190 shares issued and outstanding as of September 30, 2025 and December 31, 2024, respectively — — Additional paid-in capital 129,290,671 107,546,433 Accumulated other comprehensive loss ( 371,184 ) ( 371,184 ) Accumulated deficit ( 119,732,132 ) ( 90,687,073 ) Total shareholders' equity 9,187,355 16,488,176 Total liabilities and shareholders' equity $ 21,458,147 $ 18,911,456 The accompanying notes are an integral part of these unaudited condensed consolidated financial statements. 3 Table of Contents PROMIS NEUROSCIENCES INC. Condensed Consolidated Statements of Operations (expressed in US dollars, except share amounts) (Unaudited) For the For the For the For the Three Months Ended Three Months Ended Nine Months Ended Nine Months Ended September 30, September 30, September 30, September 30, 2025 2024 2025 2024 Operating expenses: Research and development $ 9,797,418 $ 2,563,774 $ 24,011,452 $ 6,313,373 General and administrative 1,953,014 1,870,903